Pfizer (NYSE:PFE) had its price objective reduced by analysts at Barclays from $37.00 to $35.00 in a research note issued on Monday, The Fly reports. Barclays‘s target price suggests a potential downside of 1.30% from the company’s current price.

Other research analysts have also recently issued reports about the company. Mizuho restated a “buy” rating and set a $42.00 target price on shares of Pfizer in a report on Monday, May 18th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $53.00 price target on shares of Pfizer in a research report on Thursday, March 19th. Zacks Investment Research lowered shares of Pfizer from a “buy” rating to a “hold” rating and set a $40.00 price target on the stock. in a research report on Monday, May 4th. Standpoint Research raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, February 27th. Finally, Morgan Stanley reduced their price target on shares of Pfizer from $43.00 to $36.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 2nd. Nine investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $41.03.

Shares of Pfizer stock traded down $2.73 on Monday, hitting $35.46. 72,936,628 shares of the company were exchanged, compared to its average volume of 29,408,492. The stock has a market capitalization of $212.14 billion, a price-to-earnings ratio of 12.66, a price-to-earnings-growth ratio of 2.79 and a beta of 0.70. The company has a 50-day moving average price of $37.10 and a 200 day moving average price of $36.82. Pfizer has a 1-year low of $27.88 and a 1-year high of $44.56. The company has a quick ratio of 0.78, a current ratio of 1.02 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, April 28th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.09. The business had revenue of $12.03 billion for the quarter, compared to analysts’ expectations of $11.38 billion. Pfizer had a return on equity of 25.76% and a net margin of 31.17%. The business’s revenue for the quarter was down 8.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.85 EPS. Research analysts forecast that Pfizer will post 2.8 EPS for the current year.

In other news, SVP Jennifer B. Damico sold 2,181 shares of the company’s stock in a transaction on Wednesday, April 29th. The stock was sold at an average price of $38.35, for a total transaction of $83,641.35. Following the sale, the senior vice president now owns 9,647 shares of the company’s stock, valued at $369,962.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Pfizer Inc acquired 312,500 shares of the business’s stock in a transaction dated Monday, March 16th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $5,000,000.00. The disclosure for this purchase can be found here. 0.08% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of PFE. New England Investment & Retirement Group Inc. acquired a new position in shares of Pfizer during the first quarter worth $26,000. Lion Street Advisors LLC acquired a new position in shares of Pfizer during the first quarter worth $27,000. Benjamin Edwards Inc. grew its stake in shares of Pfizer by 49.8% during the first quarter. Benjamin Edwards Inc. now owns 1,008 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 335 shares in the last quarter. Disciplined Investments LLC grew its stake in shares of Pfizer by 43.3% during the first quarter. Disciplined Investments LLC now owns 1,148 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 347 shares in the last quarter. Finally, Stonebridge Financial Planning Group LLC acquired a new position in shares of Pfizer during the fourth quarter worth $55,000. 70.28% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Featured Article: What is Elliott Wave theory?

The Fly

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.